Company news

Ironwood Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Ironwood Pharmaceuticals to Host Second Quarter 2021 Investor Update Call

July 21, 2021

Ironwood Pharmaceuticals Announces That The American Journal of Gastroenterology Publishes Full Results from Positive LINZESS® (linaclotide) Phase IIIb Trial in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)

June 15, 2021

Ironwood Pharmaceuticals Announces Leadership Updates

June 6, 2021

Ironwood Pharmaceuticals Announces Agreement with Teva Involving LINZESS® (linaclotide) 72 mcg Dosage Strength

May 25, 2021

More Than a Third of Surveyed IBS-C Patients Reported That Their Symptoms Worsened During COVID-19 According to New Survey Findings Presented by Ironwood Pharmaceuticals at Digestive Disease Week® (DDW)

May 23, 2021

Ironwood Pharmaceuticals to Present New Linaclotide Data and Unveil Findings From GI Disease Surveys at Digestive Disease Week® 2021

May 16, 2021

Ironwood Pharmaceuticals Reports First Quarter 2021 Results

May 5, 2021

Ironwood Pharmaceuticals Announces New $150 Million Share Repurchase Program

May 5, 2021

Ironwood Pharmaceuticals to Host First Quarter 2021 Investor Update Call

April 21, 2021

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial Guidance

February 16, 2021

Ironwood Pharmaceuticals Announces CEO Transition

February 7, 2021

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Investor Update Call

February 2, 2021

Ironwood Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

January 4, 2021

Ironwood Pharmaceuticals Appoints Jay P. Shepard to Board of Directors

December 2, 2020

Ironwood Pharmaceuticals to Present at the 29th Annual Credit Suisse Healthcare Conference

November 5, 2020

Ironwood Pharmaceuticals Reports Strong Third Quarter 2020 Results and Increases Full Year 2020 Financial Guidance

November 4, 2020

Ironwood Pharmaceuticals Appoints Alexander Denner, Ph.D., to Board of Directors

November 4, 2020

Ironwood Pharmaceuticals to Host Third Quarter 2020 Investor Update Call

October 21, 2020

Ironwood to Discontinue IW-3718 Development Program Following Results from Planned Efficacy Assessment

September 28, 2020

Ironwood Pharmaceuticals Reports Second Quarter 2020 Results; Delivered GAAP Net Income of $25 Million and Adjusted EBITDA of $33 Million

August 5, 2020

Ironwood Pharmaceuticals to Host Second Quarter 2020 Investor Update Call

July 22, 2020

Ironwood Announces Updates Designed to Strengthen IW-3718 Phase III Program for Refractory Gastroesophageal Reflux Disease (GERD)

July 20, 2020

Ironwood and AbbVie Report Top-line Phase II Data for MD-7246 in Patients with Abdominal Pain Associated with Irritable Bowel Syndrome with Diarrhea (IBS-D)

May 26, 2020

Ironwood Pharmaceuticals Reports First Quarter 2020 Results and Provides Update on Impact of COVID-19 Pandemic

May 5, 2020

Ironwood and Allergan Receive Notices of Allowance for Patent Applications Covering 72 mcg Dose of LINZESS® (linaclotide)

April 27, 2020

Ironwood Pharmaceuticals to Host First Quarter 2020 Investor Update Call

April 15, 2020

Ironwood Pharmaceuticals Provides Update on Impact of COVID-19

March 25, 2020

Ironwood Pharmaceuticals Announces Publication of Positive IW-3718 Phase IIb Data in Gastroenterology

February 25, 2020

Ironwood Pharmaceuticals to Present at Upcoming March Investor Conferences

February 24, 2020

Ironwood Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference

February 18, 2020

Ironwood Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2019 Results, Exceeding Full Year 2019 Guidance; Provides Full Year 2020 Guidance

February 12, 2020

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2019 Investor Update Call

January 29, 2020

Ironwood and Allergan Announce Settlement with Teva Resolving LINZESS® (linaclotide) Patent Litigation

January 21, 2020

Ironwood and Allergan Announce Settlement Resolving LINZESS® (linaclotide) Patent Litigation

January 5, 2020

Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

January 1, 2020

Ironwood Pharmaceuticals to Present at the 28th Annual Credit Suisse Healthcare Conference

November 4, 2019

Ironwood Pharmaceuticals Reports Third Quarter 2019 Results; Raises Full Year 2019 Guidance

October 30, 2019

Ironwood Pharmaceuticals to Highlight New Data at the American College of Gastroenterology 2019 Annual Scientific Meeting

October 27, 2019

Ironwood Pharmaceuticals to Host Third Quarter 2019 Investor Update Call

October 16, 2019

Ironwood Pharmaceuticals and AstraZeneca Amend LINZESS® (linaclotide) Collaboration in China

September 17, 2019

Ironwood Pharmaceuticals Announces Adjustment of Conversion Rate for its 2.25% Convertible Senior Notes due 2020

April 15, 2019

Ironwood Pharmaceuticals Completes Separation of Cyclerion Therapeutics and Becomes a Gastrointestinal (GI)-focused Healthcare Company

March 31, 2019

← Newer news releases

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 53 decks. Every deck is listed under its year.